PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

Relamorelin — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

Relamorelin (RM-131) is a selective ghrelin receptor agonist; in a 12-week phase 2B study in 393 people with diabetic gastroparesis, vomiting frequency fell 75% from baseline, but not significantly more than on placebo. · pmid:28760384

Mechanism

In 16 healthy volunteers, a single subcutaneous dose increased contractions of the distal stomach after a meal without changing gastric volumes, accommodation or satiation. · pmid:27283792

Identity

PubChem CID 44251769: Relamorelin, C43H50N8O5S, 791.0 g/mol. · pubchem:44251769

CAS registry number 661472-41-9. · pubchem:44251769

IUPAC name: 4-[[(2S)-2-[[(2R)-2-[[(2R)-3-(1-benzothiophen-3-yl)-2-(piperidine-4-carbonylamino)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]piperidine-4-carboxamide. · pubchem:44251769

Where the evidence actually sits

Emerging100%

Proportion of the 2 claims about Relamorelin standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

Effects of ghrelin receptor agonist, relamorelin, on gastric motor functions and satiation in healthy volunteers. (2016) · emergingEfficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study. (2017) · emerging20162017

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Relamorelin yet.

Dose evidence, rung by rung

No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier

    nothing resolved on this rung

  3. Observational evidence · resolved human data at the emerging tier: thin, or contested
    • Effects of ghrelin receptor agonist, relamorelin, on gastric motor functions and satiation in healthy volunteers. · pmid 27283792 · 2016
    • Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study. · pmid 28760384 · 2017
  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work

    nothing resolved on this rung

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.